Interferon lambda as a potential new therapeutic for hepatitis C

Annals of the New York Academy of Sciences

Volumn 1182, Issue , 2009, Pages 80-87

  Miller, Dennis M ^a   Klucher, Kevin M ^a   Freeman, Jeremy A ^a   Hausman, Diana F ^b   Fontana, David ^a   Williams, Doug E ^a  

^a ZYMOGENETICS INC   (United States)

^b Oncothyreon   (United States)

Author keywords

Cytokines; Hepatitis C; Interferon ; PEG IFN

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; INTERFERON RECEPTOR; INTERLEUKIN 29; LAMBDA INTERFERON RECEPTOR; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; PEGINTERFERON LAMBDA; PEGYLATED INTERLEUKIN 29; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; ANTIVIRAL ACTIVITY; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOPENIA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FIBRINOGEN BLOOD LEVEL; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; NEUTROPENIA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECURRENT DISEASE; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALIA; HEPATITIS C VIRUS;

EID: 73849096535     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05241.x     Document Type: Conference Paper

References (20)

1. Sheppard, P. et al. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4: 63-68.
2. Kotenko, S.V. et al. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4: 69-77.
3. Ank,N.,H.West&S.R. Paludan. 2006. IFN-lambda: novel antiviral cytokines. J. Interferon Cytokine Res. 26: 373-379.
4. Kotenko, S.V. & R.P. Donnelly. 2006. The IFNlambda family (IL-28/29). Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 5: 279-285.
5. Li, M. et al. 2009. Interferon-lambdas: The modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol. 86: 23-32.
6. Samuel, C.E. 2001. Antiviral actions of interferons. Clin. Microbiol. Rev. 14: 778-809.
7. Stark, G.R. et al. 1998. How cells respond to interferons. Annu. Rev. Biochem. 67: 227-264.
8. Mihm, S. et al. 2004. Interferon type I gene expression in chronic hepatitis C. Lab. Invest. 84: 1148-1159.
9. Meager, A. et al. 2005. Biological activity of interleukins-28 and-29: Comparison with type I interferons. Cytokine 31: 109-118.
10. Robek, M.D., B.S. Boyd & F.V. Chisari. 2005. Lambda interferon inhibits hepatitis B and C virus replication. J. Virol. 79: 3851-3854.
11. Zhu, H. et al. 2005. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol. J. 2: 80.
12. Ank,N. et al. 2006. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 80: 4501-4509.
13. Doyle, S.E. et al. 2006. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44: 896-906.
14. Sommereyns, C. et al. 2008. IFN-lambda (IFNlambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 4: E1000017.
15. Summary Basis of Approval for Peg-Intron (Peginterferon alfa 2b), Toxicologist's Review. FDA website, 2001. pp. 1-60.
16. Buraglio, M. et al. 1999. Recombinant human interferon-beta-1a (Rebif®) vs recombinant interferon-beta-1b (Betaseron®) in healthy volunteers. Clin. Drug Invest. 18: 27-34.
17. Carreno, V. et al. 2000. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J. Hepatol. 32: 317-324.
18. Witt, P.L. et al. 1993. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta. J. Immunother. 13: 191-200.
19. Hausman, D.F. et al. 2007. Abstract 67: A phase 1, randomized, blinded, placebo-controlled, singledose, dose-escalation study of PEG-interferon lamda (PEG-rIL-29) in healthy subjects HEP DART 2007. Frontiers in Drug Development for Viral Hepatitis 3(Supp 2): 71-72.
20. Lawitz, E. et al. 2008. Phase 1b dose-escalation study of PEG-interferon-lambda (PEG-rIL-29) in relapsed chronic hepatitis C patients; abstract 170. Hepatology 48(4 Suppl): 385A.